2025-08-01 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, formatted for clarity and readability.

## JNJ Stock Analysis (Johnson & Johnson)

**Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 10.96%
*   **VOO Cumulative Return:** 83.19%
*   **Absolute Divergence:** -72.23%
*   **Relative Divergence:** 7.1% (This indicates that JNJ's performance is in the 7.1th percentile of its historical range compared to VOO.)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the analyzed period. The relative divergence suggests that this underperformance is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD       | Alpha    | Beta   | Cap(B)  |
|------------|----------|-----------|----------|--------|---------|
| 2015-2017  | -1.0%    | 0.0%      | -4.0%    | -0.9   | 336.5   |
| 2016-2018  | -9.0%    | 56.5%     | -4.0%    | -0.0   | 310.8   |
| 2017-2019  | 7.0%     | 56.5%     | -16.0%   | -0.1   | 351.3   |
| 2018-2020  | 22.0%    | 58.6%     | -5.0%    | -0.0   | 379.0   |
| 2019-2021  | 35.0%    | 59.4%     | -14.0%   | -0.0   | 412.0   |
| 2020-2022  | 12.0%    | 61.3%     | 5.0%     | 0.1    | 425.4   |
| 2021-2023  | -9.0%    | 61.3%     | -29.0%   | 0.5    | 377.5   |
| 2022-2024  | -28.0%   | 61.3%     | -55.0%   | 0.3    | 348.3   |
| 2023-2025  | -3.0%    | 70.1%     | -51.0%   | 0.1    | 396.8   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate fluctuates, with some periods showing negative growth.
*   **MDD:** The Maximum Drawdown is significant in some periods, indicating considerable risk.
*   **Alpha:** Alpha is mostly negative, meaning JNJ has generally underperformed relative to its benchmark.
*   **Beta:** Beta is low, indicating that JNJ is less volatile than the market.
*   **Cap(B):** Market capitalization varies over the years.

### 2. Recent Stock Price Movements

*   **Current Price:** $164.74
*   **Previous Close:** $167.26
*   **Change:** -$1.51
*   **5-day Moving Average:** 166.93
*   **20-day Moving Average:** 162.33
*   **60-day Moving Average:** 156.38

**Analysis:** The price is currently below the 5-day moving average but above the 20 and 60-day moving averages. The recent price drop is notable (-$1.51) based on last-market information, but it is just a change in price.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3295 (Low Risk)
*   **RSI:** 63.84 (Approaching Overbought)
*   **PPO:** 0.0643
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** +0.4 (Short-term Increase)
*   **Expected Return:** -398.1% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a low-risk environment.
*   The RSI is approaching overbought territory, which could signal a potential pullback.
*   The Hybrid Signal recommends a Buy (90% of cash).
*   The negative expected return suggests significant underperformance relative to the S&P 500 over the long term.

### 4. Recent News & Significant Events

*   **[2025-07-29]** Business developments, regulatory changes, or market events.
*   **[2025-08-01]** Analyst discussions on performance and outlook.
*   **[2025-07-30]** Stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-31]** Market experts highlight risks and opportunities.

**Analysis:** The news indicates recent volatility and significant events impacting JNJ's stock, warranting careful monitoring.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-07-24 | 2.3  | 23.74 B$  |
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2024-07-25 | 1.95 | 22.45 B$  |
| 2025-07-24 | 1.95 | 22.45 B$  |

**Analysis:** The EPS and revenue figures show fluctuations, suggesting variability in performance.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $23.74B   | 67.87%        |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE    |
|------------|-----------|--------|
| 2025-06-30 | $78.47B  | 7.06%  |
| 2025-03-31 | $78.11B  | 14.08% |
| 2024-12-31 | $71.49B  | 4.80%  |
| 2024-09-30 | $70.16B  | 3.84%  |
| 2024-06-30 | $71.54B  | 6.55%  |

**Analysis:**

*   Revenue is relatively stable but increased recently.
*   Profit margins are consistently high.
*   Equity has increased over the observed period.
*   ROE fluctuates, indicating variability in profitability.

### 7. Overall Summary

JNJ has significantly underperformed the S&P 500, with a concerning negative expected return. Recent news suggests volatility and significant events. While the MRI indicates a low-risk environment and the Hybrid Signal recommends a buy, the RSI is approaching overbought conditions. Financial data reveals high-profit margins and increasing equity, but fluctuating ROE.

**Recommendation:** Given the underperformance, volatility, and negative expected return, investors should exercise caution and closely monitor JNJ's upcoming news and financial results. The Hybrid Signal suggests a possible entry point, but further due diligence is warranted.
